ES2236738T3 - Composicion para mejorar la digestibilidad y la utilizacion de nutrientes. - Google Patents

Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.

Info

Publication number: ES2236738T3
Authority: ES; Spain
Prior art keywords: enzyme; composition; lipase; activity; complex
Prior art date: 1995-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES96920782T

Other languages

English (en)

Spanish (es)

Inventor

Simon Lodewijk Scharpe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medzyme NV

Original Assignee

Medzyme NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-31

Filing date

1996-05-31

Publication date

2005-07-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2236738(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-05-31 Application filed by Medzyme NV filed Critical Medzyme NV

2005-07-16 Application granted granted Critical

2005-07-16 Publication of ES2236738T3 publication Critical patent/ES2236738T3/es

2016-05-31 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 48
235000015097 nutrients Nutrition 0.000 title claims abstract description 12
235000019621 digestibility Nutrition 0.000 title claims abstract description 9
108090001060 Lipase Proteins 0.000 claims abstract description 57
102000004882 Lipase Human genes 0.000 claims abstract description 57
239000004367 Lipase Substances 0.000 claims abstract description 57
235000019421 lipase Nutrition 0.000 claims abstract description 57
102000013142 Amylases Human genes 0.000 claims abstract description 55
108010065511 Amylases Proteins 0.000 claims abstract description 55
235000019418 amylase Nutrition 0.000 claims abstract description 54
239000004382 Amylase Substances 0.000 claims abstract description 49
239000002253 acid Substances 0.000 claims abstract description 34
241000228245 Aspergillus niger Species 0.000 claims abstract description 19
241000588264 Rhizopus javanicus Species 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
240000005384 Rhizopus oryzae Species 0.000 claims abstract description 5
235000013752 Rhizopus oryzae Nutrition 0.000 claims abstract description 5
208000007848 Alcoholism Diseases 0.000 claims abstract description 4
201000007930 alcohol dependence Diseases 0.000 claims abstract description 4
102000004190 Enzymes Human genes 0.000 claims description 65
108090000790 Enzymes Proteins 0.000 claims description 65
229940088598 enzyme Drugs 0.000 claims description 65
230000000694 effects Effects 0.000 claims description 56
229920002472 Starch Polymers 0.000 claims description 18
235000019698 starch Nutrition 0.000 claims description 18
239000008107 starch Substances 0.000 claims description 18
108010019160 Pancreatin Proteins 0.000 claims description 14
230000002538 fungal effect Effects 0.000 claims description 14
229940055695 pancreatin Drugs 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 14
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 13
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 11
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 11
201000003883 Cystic fibrosis Diseases 0.000 claims description 10
102100022624 Glucoamylase Human genes 0.000 claims description 10
239000004005 microsphere Substances 0.000 claims description 9
230000029087 digestion Effects 0.000 claims description 8
150000002632 lipids Chemical class 0.000 claims description 8
150000007513 acids Chemical class 0.000 claims description 7
208000035467 Pancreatic insufficiency Diseases 0.000 claims description 6
230000015556 catabolic process Effects 0.000 claims description 6
238000006731 degradation reaction Methods 0.000 claims description 6
201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
108010028144 alpha-Glucosidases Proteins 0.000 claims description 5
102000016679 alpha-Glucosidases Human genes 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
230000000968 intestinal effect Effects 0.000 claims description 5
230000002366 lipolytic effect Effects 0.000 claims description 4
230000002797 proteolythic effect Effects 0.000 claims description 4
239000006188 syrup Substances 0.000 claims description 4
235000020357 syrup Nutrition 0.000 claims description 4
208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
230000003115 biocidal effect Effects 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 3
150000007523 nucleic acids Chemical class 0.000 claims description 3
102000039446 nucleic acids Human genes 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims description 3
150000003904 phospholipids Chemical class 0.000 claims description 3
239000000975 dye Substances 0.000 claims description 2
239000008188 pellet Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
229940025131 amylases Drugs 0.000 abstract description 6
230000001684 chronic effect Effects 0.000 abstract description 5
206010033645 Pancreatitis Diseases 0.000 abstract description 3
210000003020 exocrine pancreas Anatomy 0.000 abstract description 3
230000009291 secondary effect Effects 0.000 abstract 1
229940040461 lipase Drugs 0.000 description 40
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
239000008103 glucose Substances 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 9
238000000034 method Methods 0.000 description 9
238000000746 purification Methods 0.000 description 9
210000000496 pancreas Anatomy 0.000 description 8
238000012360 testing method Methods 0.000 description 8
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
235000013305 food Nutrition 0.000 description 7
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
239000005695 Ammonium acetate Substances 0.000 description 6
229940043376 ammonium acetate Drugs 0.000 description 6
235000019257 ammonium acetate Nutrition 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000002183 duodenal effect Effects 0.000 description 6
210000001198 duodenum Anatomy 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
239000003833 bile salt Substances 0.000 description 5
229940093761 bile salts Drugs 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000001819 pancreatic juice Anatomy 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 4
230000006866 deterioration Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229920002271 DEAE-Sepharose Polymers 0.000 description 3
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000968489 Rhizomucor miehei Lipase Proteins 0.000 description 3
102000004139 alpha-Amylases Human genes 0.000 description 3
108090000637 alpha-Amylases Proteins 0.000 description 3
229940024171 alpha-amylase Drugs 0.000 description 3
230000003625 amylolytic effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229940069428 antacid Drugs 0.000 description 3
239000003159 antacid agent Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
229960001380 cimetidine Drugs 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000006870 function Effects 0.000 description 3
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000758 substrate Substances 0.000 description 3
150000003626 triacylglycerols Chemical group 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
206010025476 Malabsorption Diseases 0.000 description 2
208000004155 Malabsorption Syndromes Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010058667 Oral toxicity Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229940124301 concurrent medication Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000004130 lipolysis Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
231100000418 oral toxicity Toxicity 0.000 description 2
230000036407 pain Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000291 postprandial effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229940121819 ATPase inhibitor Drugs 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000001674 Agaricus brunnescens Nutrition 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017856 Gastritis alcoholic Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
102000003710 Histamine H2 Receptors Human genes 0.000 description 1
108090000050 Histamine H2 Receptors Proteins 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
101710084373 Lipase 1 Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 1
108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241000009328 Perro Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000235402 Rhizomucor Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
206010041969 Steatorrhoea Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010060926 abdominal symptom Diseases 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
201000005988 alcoholic gastritis Diseases 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
229940023509 aspergillus niger preparation Drugs 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
102000005311 colipase Human genes 0.000 description 1
108020002632 colipase Proteins 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
235000021472 generally recognized as safe Nutrition 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
150000004667 medium chain fatty acids Chemical class 0.000 description 1
229950003251 metiamide Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960005249 misoprostol Drugs 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
229940062190 pancreas extract Drugs 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000009666 routine test Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
150000004666 short chain fatty acids Chemical class 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000013097 stability assessment Methods 0.000 description 1
208000001162 steatorrhea Diseases 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Nutrition Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Fodder In General (AREA)
Sewing Machines And Sewing (AREA)

ES96920782T 1995-05-31 1996-05-31 Composicion para mejorar la digestibilidad y la utilizacion de nutrientes. Expired - Lifetime ES2236738T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP95201438		1995-05-31
EP95201438		1995-05-31

Publications (1)

Publication Number	Publication Date
ES2236738T3 true ES2236738T3 (es)	2005-07-16

Family

ID=8220345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES96920782T Expired - Lifetime ES2236738T3 (es)	1995-05-31	1996-05-31	Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.

Country Status (8)

Country	Link
US (1)	US6051220A (de)
EP (1)	EP0828509B1 (de)
AT (1)	ATE287725T1 (de)
AU (1)	AU6221496A (de)
CA (1)	CA2222682A1 (de)
DE (1)	DE69634248T2 (de)
ES (1)	ES2236738T3 (de)
WO (1)	WO1996038170A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100497610C (zh)	1996-12-06	2009-06-10	阿温蒂斯药物公司	人脂酶样基因编码的多肽及利用它的组合物和方法
US6140475A (en) *	1997-04-11	2000-10-31	Altus Biologics Inc.	Controlled dissolution crosslinked protein crystals
JP2000226335A (ja) *	1998-12-04	2000-08-15	Amano Pharmaceut Co Ltd	経口用酵素製剤、酵素含有食材及び酵素製剤の服用方法
US20010046493A1 (en) *	2000-02-24	2001-11-29	Alex Margolin	Lipase-containing composition and methods of use thereof
IT1319655B1 (it)	2000-11-15	2003-10-23	Eurand Int	Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AUPS076502A0 (en) *	2002-02-26	2002-03-21	Ceramic Fuel Cells Limited	A fuel cell gas separator plate
US7142464B2 (en) *	2003-04-29	2006-11-28	Saifun Semiconductors Ltd.	Apparatus and methods for multi-level sensing in a memory array
US20070087086A1 (en) *	2003-12-02	2007-04-19	Novozymes A/S	Method for producing potato products
PL1729797T3 (pl) *	2004-03-22	2009-02-27	Abbott Laboratories Gmbh	Doustne kompozycje farmaceutyczne produktów zawierających lipazę, a zwłaszcza pankreatynę, zawierające środki powierzchniowo czynne
BRPI0510817A (pt) *	2004-05-24	2007-11-20	Novozymes As	protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
ES2614157T3 (es) *	2004-10-14	2017-05-29	Eli Lilly And Co.	Composiciones que contienen lipasa, proteasa y amilasa para el tratamiento de la insuficiencia pancreática
JP2008546396A (ja) *	2005-06-24	2008-12-25	ノボザイムスアクティーゼルスカブ	薬学的に使用するためのアミラーゼ
BRPI0614914A2 (pt) *	2005-07-29	2011-04-19	Solvay Pharm Gmbh	processos para a fabricação de pó de pancreatina esterilizada
US11266607B2 (en)	2005-08-15	2022-03-08	AbbVie Pharmaceuticals GmbH	Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en)	2005-08-15	2015-12-01	Abbott Products Gmbh	Delayed release pancreatin compositions
WO2007034627A1 (ja) *	2005-09-20	2007-03-29	Idemitsu Kosan Co., Ltd.	動物用飼料添加剤
AU2006298348B8 (en) *	2005-10-05	2012-02-02	Asahi Breweries, Ltd.	Method of producing filamentous fungus culture product
US20100196344A1 (en) *	2005-10-14	2010-08-05	Cystic Fibrosis Foundation Therapeutics, Inc.	Compositions and methods for treating pancreatic insufficiency
US8071089B2 (en) *	2005-11-01	2011-12-06	Bio-Cat, Inc.	Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) *	2006-05-22	2018-09-11	Abbott Products Gmbh	Process for separating and determining the viral load in a pancreatin sample
AR065405A1 (es) *	2007-02-20	2009-06-03	Eurand Pharmaceuticals Ltd	Composiciones estables de enzimas digestivas
ES2732293T3 (es)	2007-02-22	2019-11-21	Childrens Hospital & Res Center At Oakland	Formulaciones de ácidos grasos y métodos para el uso de las mismas
US20090130063A1 (en) *	2007-11-15	2009-05-21	Solvay Pharmaceuticals Gmbh	Process for separating and determining the viral load in a pancreatin sample
KR20100092450A (ko) *	2007-12-04	2010-08-20	노보자임스 에이/에스	약학적 사용을 위한 프로테아제 변이체
WO2009109856A2 (en)	2008-03-07	2009-09-11	Axcan Pharma Inc.	Method for detecting infectious parvovirus in pharmaceutical preparations
US20110171294A1 (en) *	2008-09-30	2011-07-14	Dsm Ip Assets B.V.	Enzyme composition and application thereof in the treatment of pancreatic insufficiency
WO2010130622A1 (en) *	2009-05-11	2010-11-18	Dsm Ip Assets B.V.	Enzyme composition for the treatment of prancreatic insufficiency
AU2011228743A1 (en) *	2010-03-19	2012-10-11	Aptalis Pharma Canada, Inc.	Gastro-resistant enzyme pharmaceutical compositions
EP2621476B8 (de)	2010-10-01	2020-12-23	Société des Produits Nestlé S.A.	Enterale beschichtete pancrelipase-formulierungen mit geringer festigkeit
CN103732245B (zh)	2011-08-08	2016-07-06	阿普塔利斯制药有限公司	用于含有消化酶的组合物的溶出度测试的方法
US8268305B1 (en)	2011-09-23	2012-09-18	Bio-Cat, Inc.	Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
AU2013318686B2 (en)	2012-09-19	2017-11-30	Grespo Ab	Compositions for improvement of brain function
ES2707211T3 (es)	2013-03-15	2019-04-02	Allergan Pharmaceuticals Int Ltd	Proceso para la preparación de una composición que contiene enzimas digestivas y nutrientes adecuada para su administración enteral
WO2015019198A2 (en)	2013-07-22	2015-02-12	Aptalis Pharma S.R.L.	High potency pancreatin pharmaceutical compositions
MX2016001593A (es)	2013-08-09	2016-09-29	Allergan Pharmaceuticals Int Ltd	Composicion de enzima digestiva adecuada para administracion enterica.
RU2015155470A (ru)	2013-11-05	2017-08-21	Апталис Фарма Лтд.	Высокоэффективные фармацевтические композиции панкреатина
EP3157568A1 (de)	2014-06-19	2017-04-26	Aptalis Pharma Limited	Verfahren zur entfernung von viralen verunreinigungen aus pankreatischen extrakten
GB201501081D0 (en)	2015-01-22	2015-03-11	Cilian Ag	Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US20180028454A1 (en)	2015-02-04	2018-02-01	Abbvie Inc.	Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency
FR3079146B1 (fr)	2018-03-23	2020-04-17	Karim Ioualalen	Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1084431A (en) *	1964-05-06	1967-09-20	Analyses Et De Rech S Biolog M	Improvements in and relating to lipases
DE2638088C3 (de) *	1976-08-24	1979-06-21	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt	Verwendung von SuBmolkenpulver
FR2362863A1 (fr) *	1976-08-24	1978-03-24	Degussa	Preparations de lipases a action amelioree et preparations medicales ameliorees contenant des lipases d'origine non animale
DK0387945T3 (da) *	1989-03-08	1993-12-20	Simon Lodewijk Scharpe	Middel til behandling af eksokrin pancresinsufficiens og midlets anvendelse til fremstilling af et lægemiddel til behandlingen
BE1005445A3 (fr) *	1991-10-16	1993-07-27	Enzymes And Derivates Belgium	Compositions enzymatiques d'aide a la digestion.
US5260074A (en) *	1992-06-22	1993-11-09	Digestive Care Inc.	Compositions of digestive enzymes and salts of bile acids and process for preparation thereof

1996
- 1996-05-31 AT AT96920782T patent/ATE287725T1/de not_active IP Right Cessation
- 1996-05-31 DE DE69634248T patent/DE69634248T2/de not_active Expired - Fee Related
- 1996-05-31 ES ES96920782T patent/ES2236738T3/es not_active Expired - Lifetime
- 1996-05-31 EP EP96920782A patent/EP0828509B1/de not_active Revoked
- 1996-05-31 CA CA002222682A patent/CA2222682A1/en not_active Abandoned
- 1996-05-31 AU AU62214/96A patent/AU6221496A/en not_active Abandoned
- 1996-05-31 US US08/973,031 patent/US6051220A/en not_active Expired - Fee Related
- 1996-05-31 WO PCT/EP1996/002407 patent/WO1996038170A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP0828509A1 (de)	1998-03-18
AU6221496A (en)	1996-12-18
CA2222682A1 (en)	1996-12-05
ATE287725T1 (de)	2005-02-15
DE69634248D1 (de)	2005-03-03
DE69634248T2 (de)	2006-01-12
US6051220A (en)	2000-04-18
WO1996038170A1 (en)	1996-12-05
EP0828509B1 (de)	2005-01-26

Publication	Publication Date	Title
ES2236738T3 (es)	2005-07-16	Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.
ES2614157T3 (es)	2017-05-29	Composiciones que contienen lipasa, proteasa y amilasa para el tratamiento de la insuficiencia pancreática
US8071089B2 (en)	2011-12-06	Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
ES2806098T3 (es)	2021-02-16	Procedimientos para el tratamiento dietético del síndrome del intestino irritable y la malabsorción de carbohidratos
US10596235B2 (en)	2020-03-24	Pharmaceutical preparation
US9233146B2 (en)	2016-01-12	Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US20100196344A1 (en)	2010-08-05	Compositions and methods for treating pancreatic insufficiency
US20040057944A1 (en)	2004-03-25	Microbial enzyme mixtures useful to treat digestive disorders
EP0671943B1 (de)	1999-09-08	Verwendung von enzymen insbesondere brorelain zur behandlung von nicht-infektiöser diarrhöe
Mischler et al.	1982	Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis
ES2880602T3 (es)	2021-11-25	Comprimido orodispersable que contiene burlulipasa y composición farmacéutica preparada a partir de ella
Park et al.	2023	Digestive enzyme supplementation in prescription drugs, over-the-counter drugs, and enzyme foods
ES2924573B2 (es)	2024-04-24	Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
HK1145462A (en)	2011-04-21	Compositions containing lipase, protease and amylase for treating pancreatic insufficiency
HK1145462B (en)	2018-02-15	Compositions containing lipase, protease and amylase for treating pancreatic insufficiency
HK1004193B (en)	2000-04-14	Use of enzymes, especially bromelain, in the treatment of non-infectious diarrhoea
RS55450B1 (sr)	2017-04-28	Kompozicije koje sadrže lipazu, proteazu i amilazu za lečenje pankreatične insuficijencije
HK1109068B (en)	2011-08-12	Compositions containing lipase; protease and amylase for treating pancreatic insufficiency